MCID: PNC033
MIFTS: 57

Pancreas Adenocarcinoma malady

Categories: Endocrine diseases, Cancer diseases

Aliases & Classifications for Pancreas Adenocarcinoma

Aliases & Descriptions for Pancreas Adenocarcinoma:

Name: Pancreas Adenocarcinoma 38 12
Pancreatic Adenocarcinoma 12 29 14
Adenocarcinoma of the Pancreas 12
Adenocarcinoma of Pancreas 69

Classifications:



External Ids:

Disease Ontology 12 DOID:4074
NCIt 47 C8294
SNOMED-CT 64 700423003
UMLS 69 C0281361

Summaries for Pancreas Adenocarcinoma

Disease Ontology : 12 A pancreatic carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Pancreas Adenocarcinoma, also known as pancreatic adenocarcinoma, is related to pancreatic cancer and pancreatic ductal adenocarcinoma, and has symptoms including abdominal pain, icterus and pruritus. An important gene associated with Pancreas Adenocarcinoma is SMAD4 (SMAD Family Member 4), and among its related pathways/superpathways are TGF-Beta Pathway and Cytokine Signaling in Immune system. The drugs Abraxane and Gemzar have been mentioned in the context of this disorder. Affiliated tissues include pancreas, lung and endothelial, and related phenotypes are Decreased viability and endocrine/exocrine gland

Related Diseases for Pancreas Adenocarcinoma

Diseases related to Pancreas Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 139)
id Related Disease Score Top Affiliating Genes
1 pancreatic cancer 11.4
2 pancreatic ductal adenocarcinoma 11.2
3 acinar cell carcinoma of pancreas 11.0
4 pancreatic acinar cell adenocarcinoma 10.9
5 pancreatitis 10.9
6 mitochondrial neurogastrointestinal encephalopathy disease 10.3 KRAS SMAD4 TP53
7 ampulla of vater neoplasm 10.3 CDKN2A IL7 TP53
8 clear cell adenofibroma 10.3 CDKN2A TP53
9 spondylarthropathy 10.3 CDKN2A HRAS TP53
10 paraphimosis 10.3 BRCA2 CDKN2A TP53
11 submucosal invasive colon adenocarcinoma 10.3 BRCA2 SMAD4 TP53
12 pancreatic invasive mucinous cystadenocarcinoma 10.3 BRCA2 CDKN2A IFNG
13 lacrimal gland adenoid cystic carcinoma 10.3 CDKN2A TP53
14 bilateral hypoactive labyrinth 10.3 HRAS KRAS SMAD4
15 gallbladder pleomorphic giant cell adenocarcinoma 10.3 CDKN2A HRAS TP53
16 adult epithelioid sarcoma 10.3 CDKN2A HRAS TP53
17 familial hypopituitarism 10.3 CDH1 SMAD4 TP53
18 linitis plastica 10.3 CDH1 TP53
19 malignant skin fibrous histiocytoma 10.3 HRAS KRAS
20 endometrial squamous cell carcinoma 10.3 AKT1 CDKN2A TP53
21 uterine corpus endometrial stromal sarcoma 10.3 HRAS KRAS TP53
22 striated muscle rhabdoid tumor 10.3 CDKN2A HRAS KRAS
23 arthus reaction 10.3 HRAS KRAS TP53
24 tamoxifen-related endometrial lesion 10.3 CDKN2A KRAS TP53
25 plasmacytoma 10.3 HRAS KRAS TP53
26 spastic paraplegia 1 10.3 EGFR IFNG TP53
27 adenocarcinoma 10.3
28 exudative glomerulonephritis 10.3 EGFR KRAS TP53
29 chronic monocytic leukemia 10.3 CDKN2A EGFR TP53
30 pelvic inflammatory disease 10.3 HRAS KRAS MUC1
31 thymus squamous cell carcinoma 10.3 CDKN2A EGFR TP53
32 secondary hyperparathyroidism of renal origin 10.3 CDKN2A EGFR TP53
33 cellular ependymoma 10.3 BRCA2 MUC1 TP53
34 severe pre-eclampsia 10.3 EGFR HRAS KRAS
35 herpes simplex encephalitic 6 10.3 BRCA2 SMAD4 TP53
36 intermediate malignant teratoma 10.3 CDKN2A EGFR KRAS
37 wolffian adnexal neoplasm 10.3 EGFR TP53
38 bile duct disease 10.2 EGFR HRAS KRAS
39 placental site trophoblastic tumor 10.2 CDKN2A MUC1 SMAD4 TP53
40 immunodeficiency due to a classical component pathway complement deficiency 10.2 CDKN2A EGFR MUC1
41 kidney clear cell sarcoma 10.2 EGFR HRAS KRAS
42 postpoliomyelitis syndrome 10.2 CDKN2A HRAS KRAS TP53
43 nasal cavity adenocarcinoma 10.2 BRCA2 MUC1 MUC4
44 ossifying fibromyxoid tumor 10.2 CDKN2A HRAS KRAS TP53
45 multifocal osteogenic sarcoma 10.2 CDKN2A HRAS MUC4
46 nodular cutaneous amyloidosis 10.2 CDH1 CDKN2A TP53
47 vestibular gland benign neoplasm 10.2 CDKN2A HRAS KRAS TP53
48 pityriasis rosea 10.2 CDKN2A EGFR TP53
49 gallbladder signet ring cell adenocarcinoma 10.2 CDH1 MUC1 TP53
50 lung clear cell carcinoma 10.2 HRAS MUC1 PTF1A

Graphical network of the top 20 diseases related to Pancreas Adenocarcinoma:



Diseases related to Pancreas Adenocarcinoma

Symptoms & Phenotypes for Pancreas Adenocarcinoma

UMLS symptoms related to Pancreas Adenocarcinoma:


abdominal pain, icterus, pruritus

GenomeRNAi Phenotypes related to Pancreas Adenocarcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.88 HRAS KRAS MUC1 EGFR
2 Decreased viability GR00106-A-0 9.88 KRAS
3 Decreased viability GR00221-A-1 9.88 AKT1 KRAS CDH1 CDKN2A EGFR HRAS
4 Decreased viability GR00221-A-2 9.88 AKT1 KRAS HRAS
5 Decreased viability GR00221-A-3 9.88 HRAS AKT1 CDKN2A
6 Decreased viability GR00221-A-4 9.88 AKT1 CDKN2A EGFR
7 Decreased viability GR00301-A 9.88 KRAS CDH1
8 Decreased viability GR00381-A-1 9.88 KRAS
9 Decreased cell migration GR00055-A-1 9.35 AKT1 EGFR HRAS KRAS MUC1

MGI Mouse Phenotypes related to Pancreas Adenocarcinoma:

44 (show all 24)
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.42 AKT1 BRCA2 CDH1 CDKN2A EGFR ERCC1
2 growth/size/body region MP:0005378 10.41 SLC29A1 SMAD4 TP53 AKT1 BRCA2 CDH1
3 behavior/neurological MP:0005386 10.4 FOXP3 HRAS IFNG KRAS PTF1A SLC29A1
4 homeostasis/metabolism MP:0005376 10.39 IFNG KRAS PTF1A SLC29A1 SMAD4 TP53
5 cellular MP:0005384 10.38 FOXP3 IFNG KRAS PTF1A SMAD4 TP53
6 hematopoietic system MP:0005397 10.37 AKT1 BRCA2 CDKN2A EGFR ERCC1 FOXP3
7 cardiovascular system MP:0005385 10.35 AKT1 CDH1 CDKN2A EGFR FOXP3 HRAS
8 immune system MP:0005387 10.35 IFNG IL7 KRAS PTF1A SMAD4 TP53
9 embryo MP:0005380 10.32 KRAS PTF1A SMAD4 TP53 AKT1 BRCA2
10 mortality/aging MP:0010768 10.32 AKT1 BRCA2 CDH1 CDKN2A EGFR ERCC1
11 integument MP:0010771 10.3 FOXP3 HRAS IFNG KRAS SMAD4 TP53
12 digestive/alimentary MP:0005381 10.29 BRCA2 CDH1 CDKN2A EGFR FOXP3 IFNG
13 neoplasm MP:0002006 10.21 AKT1 BRCA2 CDH1 CDKN2A EGFR ERCC1
14 craniofacial MP:0005382 10.2 EGFR FOXP3 HRAS IFNG KRAS PTF1A
15 liver/biliary system MP:0005370 10.19 AKT1 CDKN2A EGFR ERCC1 FOXP3 IFNG
16 nervous system MP:0003631 10.14 KRAS PTF1A SLC29A1 SMAD4 TP53 AKT1
17 limbs/digits/tail MP:0005371 10.11 KRAS PTF1A SLC29A1 SMAD4 TP53 BRCA2
18 no phenotypic analysis MP:0003012 10.11 CDH1 CDKN2A EGFR FOXP3 HRAS IFNG
19 normal MP:0002873 10.1 AKT1 BRCA2 CDH1 EGFR FOXP3 HRAS
20 muscle MP:0005369 10.06 AKT1 CDKN2A EGFR ERCC1 IFNG KRAS
21 reproductive system MP:0005389 9.9 AKT1 BRCA2 CDH1 CDKN2A EGFR ERCC1
22 renal/urinary system MP:0005367 9.86 EGFR ERCC1 FOXP3 HRAS IFNG KRAS
23 respiratory system MP:0005388 9.61 AKT1 CDKN2A EGFR FOXP3 HRAS IFNG
24 skeleton MP:0005390 9.44 BRCA2 CDKN2A EGFR ERCC1 HRAS IFNG

Drugs & Therapeutics for Pancreas Adenocarcinoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Abraxane 17 46 PACLITAXEL Celgene Approved October 2012
2
Gemzar 17 46 GEMCITABINE HYDROCHLORIDE Eli Lilly Approved May 1996
3
Sutent 17 46 SUNITINIB MALATE Pfizer Approved May 2011/ Approved January 2006

Drugs for Pancreas Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 482)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
2
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 95058-81-4 60750
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
4
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
5
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
6
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 154361-50-9 60953
7
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
8
Secretin Approved, Investigational Phase 4,Phase 1,Phase 2,Early Phase 1 108153-74-8
9
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
10
Pancrelipase Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53608-75-6
11
Somatostatin Approved Phase 4,Phase 2,Phase 3,Phase 1 38916-34-6, 51110-01-1 53481605
12
Ethanol Approved Phase 4,Phase 2,Phase 1 64-17-5 702
13
Nicotine Approved Phase 4 54-11-5 942 89594
14
Zinc Approved Phase 4,Phase 2 7440-66-6 32051 23994
15
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
16
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 2078-54-8 4943
17
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
18
Etomidate Approved Phase 4 33125-97-2 36339 667484
19
Meperidine Approved Phase 4 57-42-1 4058
20
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
21
lanreotide Approved Phase 4,Phase 2,Phase 3,Phase 1 108736-35-2
22
Desflurane Approved Phase 4 57041-67-5 42113
23 pancreatin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 pancreatic polypeptide Phase 4,Phase 2,Phase 3,Phase 1
25 Analgesics Phase 4,Phase 3,Phase 1,Phase 2
26 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
27 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
31 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
34 Hypoglycemic Agents Phase 4,Phase 2,Phase 1,Early Phase 1
35 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
42 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Antimitotic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
44 Antineoplastic Agents, Phytogenic Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
45 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 insulin Phase 4,Phase 1,Phase 2
47
Dexlansoprazole Phase 4 138530-94-6, 103577-45-3 9578005
48
Proton pump inhibitors Phase 4,Phase 3,Phase 2
49 Cholinergic Agents Phase 4
50 Adjuvants, Anesthesia Phase 4,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 1112)
id Name Status NCT ID Phase
1 Efficacy of Secretin MRCP in the Diagnosis and Follow up of Auto Immune Pancreatitis Unknown status NCT01845467 Phase 4
2 Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture Unknown status NCT01125865 Phase 4
3 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4
4 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
5 Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic Adenocarcinoma Completed NCT00854477 Phase 4
6 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study Completed NCT00578279 Phase 4
7 Etomidate vs. Midazolam for Sedation During ERCP Completed NCT02027311 Phase 4
8 Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4
9 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
10 Treatment of Zollinger-Ellison Syndrome With Prevacid Completed NCT00204373 Phase 4
11 CTC Pancreatic Adenocarcinoma Recruiting NCT02335151 Phase 4
12 Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients Recruiting NCT02812992 Phase 4
13 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4
14 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Recruiting NCT01642875 Phase 4
15 A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer Active, not recruiting NCT02237157 Phase 4
16 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02759718 Phase 4
17 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4
18 Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET Active, not recruiting NCT03083210 Phase 4
19 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Not yet recruiting NCT02570529 Phase 4
20 Pancreatic Enzyme Suppletion in Pancreatic Cancer Withdrawn NCT01401387 Phase 4
21 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4
22 Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic Adenocarcinoma Unknown status NCT00075452 Phase 3
23 Hyperthermia European Adjuvant Trial Unknown status NCT01077427 Phase 3
24 A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer Unknown status NCT01586611 Phase 3
25 Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III) Unknown status NCT01065870 Phase 2, Phase 3
26 PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen Unknown status NCT00088660 Phase 3
27 Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer Unknown status NCT00112658 Phase 2, Phase 3
28 Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer Unknown status NCT00268411 Phase 3
29 Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas Unknown status NCT00005870 Phase 3
30 Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer Unknown status NCT00005871 Phase 3
31 RFA RCT for Pancreatic or Bile Duct Cancer Unknown status NCT02166190 Phase 3
32 Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Unknown status NCT00541021 Phase 3
33 Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer Unknown status NCT00005869 Phase 3
34 Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer Unknown status NCT00486460 Phase 3
35 Effectiveness of Microwave Ablation of Hepatocellular Carcinoma as Compared to Radiofrequency Ablation Unknown status NCT01340105 Phase 3
36 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3
37 Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Completed NCT01746979 Phase 3
38 Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas Completed NCT00844649 Phase 3
39 Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery Completed NCT00634725 Phase 3
40 Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer Completed NCT00033735 Phase 3
41 Gemcitabine or Combination Chemotherapy Followed by Chemoradiation for Stage IB, II, or III Pancreatic Cancer Completed NCT00960284 Phase 2, Phase 3
42 Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas Completed NCT00003216 Phase 3
43 Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer Completed NCT00099294 Phase 3
44 Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer Completed NCT01360853 Phase 3
45 S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer Completed NCT00075686 Phase 3
46 Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma Completed NCT00044031 Phase 3
47 Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer Completed NCT00057876 Phase 3
48 Gemcitabine With or Without Combination Chemotherapy and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery Completed NCT00416507 Phase 3
49 Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery Completed NCT00303758 Phase 3
50 Fluorouracil With or Without Cisplatin in Treating Patients With Advanced or Metastatic Cancer of the Pancreas Completed NCT00003029 Phase 3

Search NIH Clinical Center for Pancreas Adenocarcinoma

Genetic Tests for Pancreas Adenocarcinoma

Genetic tests related to Pancreas Adenocarcinoma:

id Genetic test Affiliating Genes
1 Pancreatic Adenocarcinoma 29

Anatomical Context for Pancreas Adenocarcinoma

MalaCards organs/tissues related to Pancreas Adenocarcinoma:

39
Pancreas, Lung, Endothelial, Breast, Kidney, T Cells

Publications for Pancreas Adenocarcinoma

Articles related to Pancreas Adenocarcinoma:

(show all 27)
id Title Authors Year
1
Distal Cholangiocarcinoma and Pancreas Adenocarcinoma: Are They Really the Same Disease? A 13-Institution Study from the US Extrahepatic Biliary Malignancy Consortium and the Central Pancreas Consortium. ( 28017812 )
2016
2
Pancreas Adenocarcinoma: Ascites, Clinical Manifestations, and Management Implications. ( 27262896 )
2016
3
Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma-An Infrequent Event: Elucidation of Risk Factors and Management Implications. ( 26395520 )
2015
4
Novel directions in neoadjuvant therapy for pancreas adenocarcinoma. ( 25686370 )
2015
5
Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma. ( 25726058 )
2015
6
Treatment, Outcomes, and Clinical Trial Participation in Elderly Patients With Metastatic Pancreas Adenocarcinoma. ( 26072442 )
2015
7
Has survival following pancreaticoduodenectomy for pancreas adenocarcinoma improved over time? ( 26388048 )
2015
8
A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. ( 24901360 )
2014
9
Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression. ( 23360922 )
2013
10
Adjuvant therapy for pancreas adenocarcinoma. ( 22886586 )
2013
11
Reply to an analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment. ( 23606044 )
2013
12
An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment. ( 22569992 )
2013
13
An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment. ( 23606137 )
2013
14
FOLFIRINOX in locally advanced pancreas adenocarcinoma: back to the future? ( 23704222 )
2013
15
Evolving panorama of treatment for metastatic pancreas adenocarcinoma. ( 23547071 )
2013
16
A prognostic model to identify patients with advanced pancreas adenocarcinoma who could benefit from second-line chemotherapy. ( 21382702 )
2012
17
Adjuvant therapy for pancreas adenocarcinoma: where are we going? ( 21342036 )
2011
18
Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection. ( 21360249 )
2011
19
Impact of selection bias on the utilization of adjuvant therapy for pancreas adenocarcinoma. ( 19851808 )
2010
20
[Analysis of K-ras, BRCA1/2, CHEK2 mutations and microsatellite markers (loss of heterozygosity at 9p, 17p and 18q) in sporadic pancreas adenocarcinomas]. ( 19548527 )
2009
21
Deregulation of 2 potassium channels in pancreas adenocarcinomas: implication of KV1.3 gene promoter methylation. ( 19465885 )
2009
22
Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma. ( 19421880 )
2009
23
Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. ( 16799337 )
2006
24
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. ( 15501974 )
2004
25
Anti-angiogenic treatment for peritoneal dissemination of pancreas adenocarcinoma: a study using TNP-470. ( 11173546 )
2001
26
Phenotypes correlating to metastatic properties of pancreas adenocarcinoma in vivo: the importance of surface sialyl Lewis(a) antigen. ( 8797870 )
1996
27
Lymphokine-activated killer cytotoxicity against pancreas adenocarcinoma cell lines and vascular endothelial cells. ( 7804431 )
1994

Variations for Pancreas Adenocarcinoma

ClinVar genetic disease variations for Pancreas Adenocarcinoma:

6 (show top 50) (show all 56)
id Gene Variation Type Significance SNP ID Assembly Location
1 MAP2K2 NM_030662.3(MAP2K2): c.169T> G (p.Phe57Val) single nucleotide variant Pathogenic/Likely pathogenic rs121434498 GRCh37 Chromosome 19, 4117551: 4117551
2 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic/Likely pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
3 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh37 Chromosome 18, 48593406: 48593406
4 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
5 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
6 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
7 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
8 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
9 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
10 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
11 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
12 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
13 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
14 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
15 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
16 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
17 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
18 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
19 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
20 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
21 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
22 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
23 GNAS NM_000516.5(GNAS): c.601C> T (p.Arg201Cys) single nucleotide variant Pathogenic/Likely pathogenic rs11554273 GRCh37 Chromosome 20, 57484420: 57484420
24 GNAS NM_000516.5(GNAS): c.602G> A (p.Arg201His) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh37 Chromosome 20, 57484421: 57484421
25 CTNNB1 NM_001904.3(CTNNB1): c.98C> A (p.Ser33Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
26 CTNNB1 NM_001904.3(CTNNB1): c.98C> T (p.Ser33Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
27 CTNNB1 NM_001904.3(CTNNB1): c.122C> T (p.Thr41Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913413 GRCh37 Chromosome 3, 41266125: 41266125
28 SMAD4 NM_005359.5(SMAD4): c.1081C> G (p.Arg361Gly) single nucleotide variant Pathogenic/Likely pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
29 SMAD4 NM_005359.5(SMAD4): c.1082G> A (p.Arg361His) single nucleotide variant Pathogenic/Likely pathogenic rs377767347 GRCh37 Chromosome 18, 48591919: 48591919
30 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
31 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
32 KRAS NM_033360.3(KRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs17851045 GRCh37 Chromosome 12, 25380275: 25380275
33 TP53 NM_000546.5(TP53): c.488A> G (p.Tyr163Cys) single nucleotide variant Pathogenic/Likely pathogenic rs148924904 GRCh37 Chromosome 17, 7578442: 7578442
34 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
35 TP53 NM_000546.5(TP53): c.580C> T (p.Leu194Phe) single nucleotide variant Pathogenic/Likely pathogenic rs587780071 GRCh37 Chromosome 17, 7578269: 7578269
36 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
37 TP53 NM_000546.5(TP53): c.701A> G (p.Tyr234Cys) single nucleotide variant Pathogenic/Likely pathogenic rs587780073 GRCh37 Chromosome 17, 7577580: 7577580
38 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
39 TP53 NM_000546.5(TP53): c.422G> A (p.Cys141Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587781288 GRCh37 Chromosome 17, 7578508: 7578508
40 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
41 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
42 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587782289 GRCh37 Chromosome 17, 7577575: 7577575
43 PIK3CA NM_006218.3(PIK3CA): c.353G> A (p.Gly118Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587777790 GRCh38 Chromosome 3, 179199690: 179199690
44 PIK3CA NM_006218.3(PIK3CA): c.3129G> A (p.Met1043Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913283 GRCh37 Chromosome 3, 178952074: 178952074
45 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh38 Chromosome 11, 534285: 534285
46 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
47 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic/Likely pathogenic rs786201059 GRCh37 Chromosome 17, 7577082: 7577082
48 GNAS NM_000516.5(GNAS): c.602G> T (p.Arg201Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh37 Chromosome 20, 57484421: 57484421
49 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 GRCh38 Chromosome 17, 7673796: 7673796
50 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic/Likely pathogenic rs760043106 GRCh38 Chromosome 17, 7674947: 7674947

Expression for Pancreas Adenocarcinoma

Search GEO for disease gene expression data for Pancreas Adenocarcinoma.

Pathways for Pancreas Adenocarcinoma

Pathways related to Pancreas Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 81)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.6 AKT1 CDH1 EGFR HRAS IFNG IL7
2
Show member pathways
13.41 AKT1 EGFR HRAS IFNG IL7 KRAS
3
Show member pathways
13.36 AKT1 CDH1 EGFR HRAS IL7 KRAS
4
Show member pathways
13.02 AKT1 BRCA2 CDH1 CDKN2A EGFR HRAS
5
Show member pathways
12.97 AKT1 HRAS IFNG KRAS SMAD4 TP53
6
Show member pathways
12.85 AKT1 CDH1 HRAS KRAS TP53
7
Show member pathways
12.78 AKT1 CDH1 EGFR HRAS KRAS
8
Show member pathways
12.78 AKT1 EGFR HRAS KRAS TP53
9 12.77 AKT1 EGFR HRAS KRAS TP53
10
Show member pathways
12.69 AKT1 EGFR HRAS IFNG KRAS TP53
11 12.62 AKT1 EGFR HRAS IL7 KRAS TP53
12
Show member pathways
12.61 AKT1 EGFR HRAS IFNG KRAS TP53
13 12.56 CDKN2A EGFR HRAS KRAS TP53
14
Show member pathways
12.55 AKT1 EGFR HRAS KRAS TP53
15
Show member pathways
12.5 AKT1 CDH1 EGFR HRAS KRAS MUC1
16
Show member pathways
12.49 AKT1 EGFR HRAS KRAS TP53
17 12.43 AKT1 CDKN2A HRAS KRAS SMAD4 TP53
18 12.41 CDH1 CDKN2A SMAD4 TP53
19
Show member pathways
12.41 AKT1 EGFR HRAS KRAS
20
Show member pathways
12.38 AKT1 CDH1 EGFR HRAS KRAS SMAD4
21
Show member pathways
12.36 AKT1 EGFR HRAS KRAS TP53
22 12.34 CDKN2A HRAS KRAS TP53
23
Show member pathways
12.34 AKT1 EGFR HRAS KRAS
24 12.34 AKT1 EGFR HRAS KRAS TP53
25
Show member pathways
12.31 AKT1 HRAS KRAS TP53
26
Show member pathways
12.28 AKT1 EGFR HRAS KRAS
27
Show member pathways
12.26 AKT1 HRAS IFNG IL7
28 12.24 AKT1 EGFR HRAS KRAS
29
Show member pathways
12.24 AKT1 EGFR KRAS TP53
30
Show member pathways
12.23 AKT1 HRAS KRAS TP53
31 12.21 AKT1 BRCA2 CDH1 CDKN2A EGFR HRAS
32
Show member pathways
12.19 AKT1 HRAS KRAS TP53
33
Show member pathways
12.19 AKT1 EGFR HRAS KRAS
34
Show member pathways
12.19 AKT1 HRAS KRAS TP53
35 12.16 AKT1 HRAS KRAS TP53
36 12.14 AKT1 HRAS KRAS SMAD4
37 12.13 AKT1 CDKN2A KRAS TP53
38 12.13 AKT1 CDH1 EGFR IFNG KRAS SMAD4
39
Show member pathways
12.12 AKT1 HRAS IFNG KRAS
40 12.12 AKT1 FOXP3 SMAD4 TP53
41 12.12 AKT1 CDH1 HRAS KRAS SMAD4
42
Show member pathways
12.11 AKT1 EGFR HRAS KRAS
43
Show member pathways
12.11 AKT1 EGFR HRAS KRAS SMAD4
44 12.08 AKT1 EGFR HRAS KRAS TP53
45 12.07 AKT1 CDH1 HRAS KRAS
46 12.05 AKT1 HRAS KRAS TP53
47 12.03 AKT1 HRAS KRAS TP53
48
Show member pathways
11.99 AKT1 EGFR TP53
49 11.99 AKT1 CDKN2A HRAS KRAS SMAD4 TP53
50 11.99 AKT1 BRCA2 CDH1 EGFR KRAS SMAD4

GO Terms for Pancreas Adenocarcinoma

Cellular components related to Pancreas Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.53 AKR7A3 AKT1 BRCA2 CDH1 CDKN2A EGFR

Biological processes related to Pancreas Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 26)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.96 FOXP3 HRAS IFNG KRAS TP53
2 negative regulation of cell proliferation GO:0008285 9.91 CDKN2A FOXP3 HRAS IFNG SMAD4 TP53
3 negative regulation of gene expression GO:0010629 9.87 AKT1 FOXP3 HRAS IFNG
4 cell cycle arrest GO:0007050 9.83 CDKN2A HRAS IFNG TP53
5 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.81 AKT1 CDKN2A EGFR FOXP3 HRAS IFNG
6 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.8 HRAS KRAS MUC1 MUC4
7 positive regulation of MAP kinase activity GO:0043406 9.77 EGFR HRAS KRAS
8 epidermal growth factor receptor signaling pathway GO:0007173 9.76 EGFR HRAS KRAS
9 nucleotide-excision repair GO:0006289 9.72 BRCA2 ERCC1 TP53
10 positive regulation of nitric oxide biosynthetic process GO:0045429 9.71 AKT1 EGFR IFNG
11 ERBB2 signaling pathway GO:0038128 9.69 EGFR HRAS KRAS
12 Ras protein signal transduction GO:0007265 9.67 CDKN2A HRAS KRAS TP53
13 positive regulation of protein phosphorylation GO:0001934 9.65 AKT1 EGFR HRAS IFNG KRAS
14 positive regulation of organ growth GO:0046622 9.63 AKT1 IL7
15 cell aging GO:0007569 9.63 BRCA2 HRAS TP53
16 replicative senescence GO:0090399 9.62 CDKN2A TP53
17 negative regulation of interleukin-17 production GO:0032700 9.62 FOXP3 IFNG
18 response to isolation stress GO:0035900 9.61 HRAS KRAS
19 positive regulation of smooth muscle cell apoptotic process GO:0034393 9.61 CDKN2A IFNG
20 positive regulation of cellular senescence GO:2000774 9.6 CDKN2A KRAS
21 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.58 AKT1 EGFR
22 response to X-ray GO:0010165 9.58 BRCA2 ERCC1 TP53
23 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.5 BRCA2 MUC1 TP53
24 cell proliferation GO:0008283 9.5 AKT1 BRCA2 EGFR ERCC1 HRAS SMAD4
25 response to UV-A GO:0070141 9.48 AKT1 EGFR
26 positive regulation of transcription, DNA-templated GO:0045893 9.32 AKT1 BRCA2 CDH1 CDKN2A EGFR FOXP3

Molecular functions related to Pancreas Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nitric-oxide synthase regulator activity GO:0030235 8.62 AKT1 EGFR

Sources for Pancreas Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....